BSEInsider Trading / SAST25 Aug 2026 · 25 Aug 2026, 10:57 am

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd

Dr. Agarwals Health Care Ltd · 544350

✦ AI SummaryPledge

Catalyst Trusteeship Ltd has created a pledge over 7,538,303 equity shares of Dr. Agarwal's Health Care Ltd, constituting 2.38% of the issued and paid-up share capital, as part of a facility agreement with Hyperion Investments Pte. Ltd.

Analysis Scores

Earnings Impact2/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact5/10
Market Sentiment3/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Dr. Agarwals Health Care Ltd - 544350 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Attachments (1)

📄

5F7CB3F9_1B31_4DAB_997E_BB8437259168_105656.pdf

pdf

Download →
View document text
CTL/SAST/26-27/01485 24th August 2026 1. Department of Corporate Services, BSE Limited Floor 25, P J Towers, Dalal Street, Mumbai - 400 001 2. National Stock Exchange of lndia Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 3. cc: Dr. Agarwal’s Health Care Limited 1st Floor, Buhari Towers, No. 4, Moores Road, off Greams Road, Near Asan Memorial School, Chennai, Tamil Nadu 600006 Sub: Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Dear Sir/Ma’am, We, Catalyst Trusteeship Limited (“Onshore Security Agent”), write in our capacity as a pledgee for the Shares (as defined below) of Dr. Agarwal’s Health Care Limited (“Target Company”). A facility agreement dated March 26, 2024 (“Facility Agreement”) had been entered into between, inter alia, Hyperion Investments Pte. Ltd. (“Borrower”) and certain lenders for the purpose of availing a facility aggregating up to USD 100,000,000 (“Facility”) by the Borrower. The Borrower had pledged 73,193,988 equity shares of the issued and paid-up share capital of the Target Company (“Shares”) in favour of the Onshore Security Agent, through the depository system. The Onshore Security Agent had made a disclosure on 6 February 2025 under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (the “Takeover Code”), in relation to the Target Company, as more particularly described therein as well as herein below. Pledge over 31,698,303 equity shares of the Target Company was released on 11 August 2026 and the Onshore Security Agent had made a disclosure on 13 August 2026 under Regulation 29(2) of the Takeover Code. Pledge has now been created over 7,538,303 equity shares constituting 2.38% of the issued and paid up share capital of the Target Company in favour of the Onshore Security Agent (these shares formed part of the shares previously released on 11 August 2026). Enclosed is a disclosure under Regulation 29(2) of the Takeover Code for the creation of encumbrance over 7,538,303 equity shares of the Target Company. We request you to take the same on record and acknowledge the same. Yours faithfully, For Catalyst Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: 24th August 2026 Disclosure under Regulation 29(2) of SEBl (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Name of the Target Company Dr. Agarwal’s Health Care Limited (TC) Name(s) of the acquirer and Catalyst Trusteeship Limited acting in its capacity as the Persons Acting in Concert (PAC) onshore security agent for certain lenders to Hyperion with the acquirer Investments Pte. Ltd. under the Facility Agreement (as defined below Whether the acquirer belongs to No Promoter/Promoter group Name(s) of the Stock BSE Limited and National Stock Exchange of India Limited Exchange(s) where the shares of TC are Listed % w .r.t. % w.r.t. total total diluted share/voting Details of the share/voting Number capital acquisition/disposal as follows capital of the wherever applicable(*) (**) Before the acquisition/ Nil Nil Nil disposal under consideration, holding of: (a) Shares carrying voting rights (b) Shares in the nature of 41,495,685# 13.09# 12.99# encumbrance (pledge/ lien/ non-disposal undertaking/ others) (c) Voting rights (VR) Nil Nil Nil otherwise than by equity shares (d) Warrants/convertible Nil Nil Nil securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) (e) Total (a+b+c+d) 41,495,685# 13.09# 12.99# Details of acquisition/sale/disposal (a) Shares carrying voting Nil Nil Nil rights acquired / sold (b) VRs acquired / sold Nil Nil Nil otherwise than by shares (c) Warrants/convertible Nil Nil Nil securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired / sold (d) Shares encumbered / 7,538,303# 2.38# 2.36# invoked / released by the acquirer (e) Total (a+b+c+/-d) 7,538,303# 2.38# 2.36# After the Nil Nil Nil acquisition/sale/disposal, holding of: (a) Shares carrying voting rights (b) Shares encumbered with 49,033,988# 15.47# 15.36# the acquirer (c) VRs otherwise than by Nil Nil Nil shares (d) Warrants/convertible Nil Nil Nil securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition (e) Total (a+b+c+d) 49,033,988# 15.47# 15.36# Mode of acquisition/sale (e.g. Creation of encumbrance by way of pledge. Please see note open market / off-market / public # below. issue / rights issue / preferential allotment / inter se transfer etc.) Date of acquisition/ sale of 21 August 2026 (date of creation of pledge) shares/ VR or date of receipt of intimation of allotment of shares, whichever is applicable. Equity share capital / total voting 316,983,028 fully paid up equity shares of INR 1/- each capital of the TC before the said acquisition / sale Equity share capital/ total voting 316,983,028 fully paid up equity shares of INR 1/- each capital of the TC after the said acquisition / sale Total diluted share/voting capital 319,262,876 fully paid up equity shares of INR 1/- each of the TC after the said acquisition / sale Note # 1. A facility agreement dated March 26, 2024 (“Facility Agreement”) had been entered into between, inter alia, Hyperion Investments Pte. Ltd. (“Borrower”) and certain lenders for the purpose of availing a facility aggregating up to USD 100,000,000 (“Facility”) by the Borrower. The Borrower had pledged 73,193,988 equity shares of the issued and paid-up share capital of the Target Company (“Shares”) in favour of the Onshore Security Agent, through the depository system. 2. Disclosure under Regulation 29(1) of the Takeover Code had been made with respect to this transaction by the Onshore Security Agent on 6 February 2025. 3. Pledge over 31,698,303 equity shares of the Target Company was released on 11 August 2026 and the Onshore Security Agent had made a disclosure on 13 August 2026 under Regulation 29(2) of the Takeover Code. 4. Pledge has now been created over 7,538,303 equity shares constituting 2.38% of the issued and paid up share capital of the Target Company in favour of the Onshore Security Agent (these shares formed part of the shares previously released on 11 August 2026). 5. In terms of Regulation 29 (2) read with Regulation 29 (4) of the Takeover Code, encumbrance over shares (including shares that are encumbered by way of pledge) shall be treated as an acquisition. Accordingly, this disclosure is being made in respect of the encumbrance to be created over the Shares of the Target Company, in favour of the Onshore Security Agent for the benefit of the Lenders (including their assigns, transferees, successors and novates from time to time, provided they are overseas banks or otherwise eligible to obtain the benefit of the pledge under applicable Reserve Bank of India guidelines and their agent/trustees) under the Facility as described above. For Catalyst Trusteeship Limited Authorised Signatory Name: Deesha Srikkanth Designation: Senior Vice President Place: Mumbai Date: 24th August 2026 Note: (*) Total share capital/ voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement. (**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.